November 12, 2024. Avelo starts its pneumonia study, AeroCAP, in collaboration with Prof. Dr. med. Michael Osthoff and his team at University Hospital Basel on World Pneumonia Day.
Today is World Pneumonia Day, a yearly reminder of one of the leading causes of death globally and a major driver of hospitalizations. Pneumonia is curable. Its fast and accurate diagnosis enables timely, effective treatment and ultimately saves lives. At Avelo, we are committed to making every breath count with our breath sampling solution designed to simplify and broaden access to pathogen identification and targeted treatment.
Together with the University Hospital Basel in Switzerland, we will conduct a clinical research study to assess our innovative device in real-world settings. We are excited to work with an exceptional team of experts, united in the fight against pneumonia.
About Avelo
Avelo AG, the Swiss breath aerosol diagnostic company, aims to revolutionize the diagnosis of Tuberculosis and lower respiratory tract infections causing pneumonia. Its breath collection device enables non-invasive collection of pathogens from breath and works with existing PCR tests. The novel device is designed for broad utility, similar to other sample collection technologies such as blood tubes. Founded in 2020, Avelo has a talented team experienced in business development, functional materials, product development, clinical research, molecular diagnostics, quality and regulatory, and is based in Zurich-Schlieren.
Comments